AGEN — Recent News Coverage
All news mentioning AGEN in ESEN's AI-graded feed
News stories with AGEN as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on AGEN. See /coverage/AGEN for the 30-day aggregate.
GURUFOCUS.COM
·
2026-10-25
HIGH
BULLISH
CORR0.42
Agenus (AGEN) Reports Promising Phase 2 Colon Cancer Trial Results
$AGEN
◈ ESEN AI
AGEN disclosed positive Phase 2 NEOASIS trial data for advanced colon cancer treatment, representing a clinical milestone that materially de-risks the company's pipeline. Successful Phase 2 outcomes typically catalyze r…
SEEKINGALPHA.COM
·
2026-07-15
NEUTRAL
BULLISH
CORR0.35
Agenus Surges 83% On $340 Million Financing: The Road To A 2030 Breakthrough (NASDAQ:AGEN)
$AGEN
◈ ESEN AI
AGEN posted an 83% intraday surge following announcement of a $340 million financing package, though the actual capital raise disclosed was $85 million. This discrepancy between headline valuation impact and disclosed a…
SEEKINGALPHA.COM
·
2026-07-14
NEUTRAL
NEUTRAL
CORR0.15
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer - Slideshow (NASDAQ:AGEN) 2026-07-14
$AGEN
◈ ESEN AI
Agenus Inc. (AGEN) disclosed financing plans and trial strategy updates for its Robin trial program, targeting neoadjuvant immunotherapy in microsatellite-stable (MSS) colon cancer treatment. The announcement reflects m…
RTTNEWS.COM
·
2026-07-14
NEUTRAL
BULLISH
CORR0.42
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus
$QTTB
$AGEN
$SI
◈ ESEN AI
QTTB emerged as the primary mover following positive Phase 2 efficacy data for its hair loss therapeutic, a critical inflection point for follicle-targeting treatments in a competitive dermatology market. Success at thi…
SEEKINGALPHA.COM
·
2026-07-13
NEUTRAL
NEUTRAL
CORR0.15
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
$AGEN
◈ ESEN AI
Agenus Inc. (AGEN) disclosed strategic updates on financing mechanisms and clinical trial progression for its neoadjuvant immunotherapy candidate targeting microsatellite-stable (MSS) colon cancer. The Robin trial repre…
FINANCE.YAHOO.COM
·
2026-07-13
HIGH
BULLISH
CORR0.72
Agenus shares surge as company secures up to $340M to advance colon cancer trial
$AGEN
◈ ESEN AI
AGEN delivered a dramatic 100% single-session surge following announcement of a fully oversubscribed $340M private placement. The capital raise directly funds advancement of its dual-agent immunotherapy BOT+BAL targetin…
RTTNEWS.COM
·
2026-07-13
LOW
NEUTRAL
CORR0.15
Morning Market Movers: QTTB, AGEN, JLHL, STRS See Big Swings
$QTTB
$AGEN
$JLHL
$STRS
◈ ESEN AI
This premarket snapshot identifies four micro-cap or lower-liquidity securities (QTTB, AGEN, JLHL, STRS) experiencing above-average trading activity before the 9:30 a.m. ET open. Early price swings in low-float names ar…
RTTNEWS.COM
·
2026-07-13
LOW
NEUTRAL
CORR0.15
Morning Market Movers: QTTB, AGEN, JLHL, STRS See Big Swings
$QTTB
$AGEN
$JLHL
$STRS
◈ ESEN AI
Premarket activity in QTTB, AGEN, JLHL, and STRS reflects routine opening-bell volatility typical of Monday sessions. Without disclosed fundamental catalysts—earnings announcements, guidance revisions, or material corpo…
FINANCE.YAHOO.COM
·
2026-07-13
NEUTRAL
BULLISH
CORR0.42
Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN)
$AGEN
◈ ESEN AI
AGEN announced a $85 million private placement with potential for up to $340 million in additional funding, triggering a 13% premarket rally. This financing mechanism is typical for clinical-stage biotechs managing cash…
EXPLORE OTHER FILTERS